Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals — Stockholders' equity by Quarter
Crinetics Pharmaceuticals — Stockholders' equity ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals — Stockholders' equity: $1,192M in Q2 2026, up 1.7% from a year earlier.
Where the Q2 2026 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Stockholders' equity ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,192 | +1.7% | SEC Filing ↗ |
| Q1 2026 | Mar 31, 2026 | 1,281 | +2.1% | SEC Filing ↗ |
| Q4 2025 | Dec 31, 2025 | 992 | -25.1% | SEC Filing ↗ |
| Q3 2025 | Sep 30, 2025 | 1,072 | +28.7% | SEC Filing ↗ |
| Q2 2025 | Jun 30, 2025 | 1,172 | +41.0% | SEC Filing ↗ |
| Q1 2025 | Mar 31, 2025 | 1,254 | +43.3% | SEC Filing ↗ |
| Q4 2024 | Dec 31, 2024 | 1,325 | +145.7% | SEC Filing ↗ |
| Q3 2024 | Sep 30, 2024 | 833 | +52.1% | SEC Filing ↗ |
| Q2 2024 | Jun 30, 2024 | 831 | +226.9% | SEC Filing ↗ |
| Q1 2024 | Mar 31, 2024 | 875 | +212.1% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 539 | +70.4% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 548 | +55.9% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 254 | -34.2% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 280 | -7.5% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 316 | -4.7% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 351 | +81.5% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 386 | +91.7% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 303 | +102.7% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 332 | +96.5% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 194 | +3.4% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 201 | -0.7% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 149 | +37.8% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 169 | +44.2% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 187 | +44.5% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 203 | +42.7% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 108 | -28.8% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 117 | -26.9% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 130 | -22.7% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 142 | -664.3% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 152 | -862.7% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 160 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 168 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | -25.2 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | -20.0 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals — Stockholders' equity ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-equity
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.